Multiple Myeloma Refractory research hub
7 indexed studies · 5 currently recruiting
- recruitingPHASE2
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
This study is testing a new combination of medicines – inobrodib, pomalidomide, and dexamethasone – for people in the UK with multiple myeloma that has come back and is no longer responding to usual treatments. The aim is to see how well these medicines work together and what side effects they might cause.
United States · United Kingdom - recruitingNA
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
This study looks at adding early support care for people with multiple myeloma or aggressive lymphoma. It wants to see if this helps improve their well-being, mood, and how they feel about their care, compared to standard care alone.
Canada - active not recruitingPHASE1
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
This study is looking into a new treatment called MK-4002 (or HPN217) for people with multiple myeloma that has come back or is no longer responding to usual treatments. Researchers want to find a safe dose and understand how the body handles the medicine.
United States · France · Spain - recruitingPHASE1
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
This early-stage study is testing a new cell therapy called MDC-CAR-BCMA001. It aims to find the safest dose for people with certain types of blood cancers, like some lymphomas and multiple myeloma, that have come back or not responded to other treatments.
Germany - active not recruitingPHASE3
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
This study looks at treating a type of cancer called multiple myeloma that has come back. It compares how long people take a drug combination (Dara-Len-Dex) – either for a set time (2 years) or until the cancer gets worse. The main goal is to see which approach helps people live longer.
France - recruiting
Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
This study looks at how well a new immune-boosting treatment for a type of blood cancer called multiple myeloma works when given in different ways. It compares giving the treatment at home versus in the hospital, focusing on patient quality of life and costs.
France - not yet recruitingPHASE1
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
This study is testing a new turmeric-based drug called LipoCurc for people with multiple myeloma that has come back or isn't responding to other treatments. The main goal is to find a safe dose and see what side effects it might cause.
Canada